Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.
Bruno Valentin SinnSibylle LoiblClaus A HanuschDirk-Michael ZahmHans-Peter SinnMichael UntchKarsten WeberThomas KarnClemens BeckerFrederic MarméWolfgang Daniel SchmittVolkmar MüllerChristian SchemDenise TreueElmar StickelerFrederik KlauschenNicole BurchardiJenny FurlanettoMarion van MackelenberghPeter Andreas FaschingAndreas SchneeweißCarsten DenkertPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Immune-associated signatures are associated with pCR after chemotherapy, but might be of limited use for the prediction of response to additional immune checkpoint blockade. Gene expressions related to antigen presentation and IFN signaling might be interesting candidates for further evaluation.